Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.81K$4.81Kderived— vs Q4 2020 Net Income-$8.05M-$8.05MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$7,647,504N/M Operating Cash Flowderived-$792,932N/M Free Cash Flowderived-$813,405— Margins · derivedOperating margin-159024.8%
Net margin-167377.2%
ended Dec 31, 2021 · filed Apr 15, 2022 · 105 d after period end